Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

Harb, Ola A.; Kaf, Randa Mohamed; Taha, Heba F.; Ahmed, Rham Z.; Mandour, Doaa; Al Attar, Ahmed Z.; Fathy, Ayman; Almoregy, Abdelwahab S.; Osman, Gamal; Gertallah, Loay M.

doi:10.1186/s42047-019-0038-7

Table 2 Correlation between clinicopathological features, PDL-1, FOXP-1, STAT-3 expression in our patients

From: Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

Characteristics	All	PD-L1		p-value	FOXP-1		p-value	STAT-3			p-value
	All	Low (N = 31)	High (N = 19)		Low (N = 29)	High (N = 21)		Low (N = 27)	High (N = 23)
	(N = 50)	Low (N = 31)	High (N = 19)		Low (N = 29)	High (N = 21)		Low (N = 27)	High (N = 23)
	No. (%)	No. (%)	No. (%)		No. (%)	No. (%)		No. (%)	No. (%)
Age
< 40 years	8 (16%)	8 (100%)	0 (0%)	< 0.001^b	8 (100%)	0 (0%)	< 0.001^b	6 (75%)	2 (25%)		0.003^b
40–60 years	20 (40%)	16 (80%)	4 (20%)		16 (80%)	4 (20%)		14 (70%)	6 (30%)
61–74 years	17 (34%)	6 (35.5%)	11 (64.7%)		4 (23.5%)	13 (76.5%)		7 (41.2%)	10 (58.8%)
≥ 75 years	5 (10%)	1 (20%)	4 (80%)		1 (20%)	4 (80%)		0 (0%)	5 (100%)
Sex
Male	31 (62%)	20 (64.5%)	11 (35.5%)	0.640^a	19 (61.3%)	12 (38.7%)	0.547^a	19 (61.3%)	12 (38.7%)		0.186^a
Female	19 (38%)	11 (57.9%)	8 (42.1%)	0.640^a	10 (52.6%)	9 (47.4%)	0.547^a	8 (42.1%)	11 (57.9%)		0.186^a
History of Hepatitis B
Absent	42 (84%)	27 (64.3%)	15 (35.7%)	0.459^a	27 (64.3%)	15 (35.7%)	0.056^a	25 (59.5%)	17 (40.5%)		0.121^a
Present	8 (16%)	4 (50%)	4 (50%)	0.459^a	2 (25%)	6 (75%)	0.056^a	2 (25%)	6	(75%)	0.121^a
B symptoms
Absent	31 (62%)	24 (77.4%)	7 (22.6%)	0.004^a	24 (77.4%)	7 (22.6%)	< 0.001^a	22 (71%)	9 (29%)		0.002^a
Present	19 (38%)	7 (36.8%)	12 (63.2%)	0.004^a	5 (26.3%)	14 (73.7%)	< 0.001^a	5 (26.3%)	14 (73.7%)		0.002^a
Fever
Absent	31 (62%)	24 (77.4%)	7 (22.6%)	0.004^a	24 (77.4%)	7 (22.6%)	< 0.001^a	22 (71%)	9 (29%)		0.002^a
Present	19 (38%)	7 (36.8%)	12 (63.2%)	0.004^a	5 (26.3%)	14 (73.7%)	< 0.001^a	5 (26.3%)	14 (73.7%)		0.002^a
Weight loss
Absent	31 (62%)	24 (77.4%)	7 (22.6%)	0.004^a	24 (77.4%)	7 (22.6%)	< 0.001^a	22 (71%)	9 (29%)		0.002^a
Present	19 (38%)	7 (36.8%)	12 (63.2%)	0.004^a	5 (26.3%)	14 (73.7%)	< 0.001^a	5 (26.3%)	14 (73.7%)		0.002^a
Night sweating
Absent	31 (62%)	24 (77.4%)	7 (22.6%)	0.004^a	24 (77.4%)	7 (22.6%)	< 0.001^a	22 (71%)	9 (29%)		0.002^a
Present	19 (38%)	7 (36.8%)	12 (63.2%)	0.004^a	5 (26.3%)	14 (73.7%)	< 0.001^a	5 (26.3%)	14 (73.7%)		0.002^a
ECOG Ps
ECOG 1	37 (74%)	27 (73%)	10 (27%)	0.018^a	27 (73%)	10 (27%)	< 0.001^a	23 (62.2%)	14 (37.8%)		0.051^a
ECOG 2–4	13 (26%)	4 (30.8%)	9 (69.2%)	0.018^a	2 (15.4%)	11 (84.6%)	< 0.001^a	4 (30.8%)	9 (69.2%)		0.051^a
Bulky nodes
Absent	23 (46%)	19 (82.6%)	4 (17.4%)	0.006^a	19 (82.6%)	4 (17.4%)	0.001^a	17 (73.9%)	6 (26.1%)		0.009^a
Present	27 (54%)	12 (44.4%)	15 (55.6%)	0.006^a	10 (37%)	17 (63%)	0.001^a	10 (37%)	17 (63%)		0.009^a
Extranodal involvement
Absent	23 (46%)	19 (82.6%)	4 (17.4%)	0.006^a	19 (82.6%)	4 (17.4%)	0.001^a	17 (73.9%)	6 (26.1%)		0.009^a
Present	27 (54%)	12 (44.4%)	15 (55.6%)	0.006^a	10 (37%)	17 (63%)	0.001^a	10 (37%)	17 (63%)		0.009^a
Bone marrow involvement
Absent	31 (62%)	24 (77.4%)	7 (22.6%)	0.004^a	24 (77.4%)	7 (22.6%)	< 0.001^a	22 (71%)	9 (29%)		0.002^a
Present	19 (38%)	7 (36.8%)	12 (63.2%)	0.004^a	5 (26.3%)	14 (73.7%)	< 0.001^a	5 (26.3%)	14 (73.7%)		0.002^a
LDH
≤ ULN	20 (40%)	18 (90%)	2 (10%)	< 0.001^b	18 (90%)	2 (10%)	< 0.001^b	16 (80%)	4 (20%)		0.003^b
> ULN - <3xULN	14 (28%)	9 (64.3%)	5 (35.7%)		8 (57.1%)	6 (42.9%)		6 (42.9%)	8 (57.1%)
> 3xULN	16 (32%)	4 (25%)	12 (75%)		3 (18.8%)	13 (81.2%)		5 (31.2%)	11 (68.8%)
Stage
Stage I	11 (22%)	9 (81.8%)	2 (18.2%)	0.003^b	9 (81.8%)	2 (18.2%)	0.001^b	9 (81.8%)	2 (18.2%)		0.003^b
Stage II	16 (32%)	13 (81.2%)	3 (18.8%)		13 (81.2%)	3 (18.8%)		11 (68.8%)	5 (31.2%)
Stage III	13 (26%)	6 (46.2%)	7 (53.8%)		5 (38.5%)	8 (61.5%)		4 (30.8%)	9 (69.2%)
Stage IV	10 (20%)	3 (30%)	7 (70%)		2 (20%)	8 (80%)		3 (30%)	7 (70%)
IPI risk group
Low	22 (44%)	19 (86.4%)	3 (13.6%)	0.001^b	19 (86.4%)	3 (13.6%)	< 0.001^b	17 (77.3%)	5 (22.7%)		0.005^b
Low – Intermediate	5 (10%)	3 (60%)	2 (40%)		3 (60%)	2 (40%)		3 (60%)	2 (40%)
High – Intermediate	7 (14%)	3 (42.9%)	4 (57.1%)		3 (42.9%)	4 (57.1%)		1 (14.3%)	6 (85.7%)
High	16 (32%)	6 (37.5%)	10 (62.5%)		4 (25%)	12 (75%)		6 (37.5%)	10 (62.5%)
PD-L1
Low	31 (62%)				27 (87.1%)	4 (12.9%)	< 0.001^a	26 (83.9%)	5 (16.1%)		< 0.001^a
High	19 (38%)				2 (10.5%)	17 (89.5%)	< 0.001^a	1 (5.3%)	18 (94.7%)		< 0.001^a
FOXP1
Low	29 (58%)	27 (93.1%)	2 (6.9%)	< 0.001^a				22 (75.9%)	7 (24.1%)		< 0.001^a
High	50 (42%)	4 (19%)	17 (81%)	< 0.001^a				5 (23.8%)	16 (76.2%)		< 0.001^a
STAT3
Low	27 (54%)	26 (96.3%)	1 (3.7%)	< 0.001^a	22 (81.5%)	5 (18.5%)	< 0.001^a
High	23 (46%)	5 (21.7%)	18 (78.3%)	< 0.001^a	7 (30.4%)	16 (69.6%)	< 0.001^a

Categorical variables were expressed as number (percentage); ^a Chi-square test; ^b Chi-square test for trend; p < 0.05 is significant

Back to article page

ISSN: 2520-8454

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@springeropen.com

Surgical and Experimental Pathology

Contact us